Transparent RMD Forecast & AI Summaries

---

Trade smarter with daily optimized AI models + news summaries.

ResMed's Pendarvis to retire - HME News

SAN DIEGO – ResMed has announced that David Pendarvis, chief administrative officer, global general counsel and secretary, plans to retire on June 30. He will remain in a consulting role with the company through Dec. 31, 2023. “Dave has been an integral part of ResMed for over 20 years, helping guide the company into and through its transformation from the pioneer of sleep apnea treatment to a $30 billion-plus global leader in digital health and cloud-connected medical devices,” said CEO Mick Farrell. “On behalf of the entire management team and the board, I want to thank Dave for his two decades of dedicated service and exemplary leadership that has helped build the industry-leading company that ResMed ...

hmenews.com     Apr 03, 2023

ResMed: Wait And See How The Return Of Key Competitor Will Impact ResMed

technology

ResMed (NYSE:RMD) creates, produces, and distributes medical devices for the treatment of apnea of sleep. I believe the 3Q23 performance has reset the expectations for sequential improvement in performance for the rest of CY23, especially given the improved delivery of CPAPs. While this is also largely a function of supply chain easing, removing the lid that has been constraining growth, the absence of Philips Respironics has been a driver as well – allowing RMD to capture all the demand surplus. With this in mind, I am also conscious of the fact that Philips will eventually come back, and the market share that RMD has gained over this period might not be 100% retained.

seekingalpha.com     May 06, 2023